By Mill Chart
Last update: Apr 11, 2024
Consider MERCK & CO. INC. (NYSE:MRK) as a top value stock, identified by our stock screening tool. NYSE:MRK shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. Let's dive deeper into the analysis.
ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NYSE:MRK boasts a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:MRK, the assigned 8 is noteworthy for profitability:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:MRK has earned a 7 out of 10:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NYSE:MRK scores a 4 out of 10:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of MRK
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
MERCK & CO. INC.
NYSE:MRK (4/29/2024, 2:49:09 PM)
129.56
-1.64 (-1.25%)
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
MRK earnings call for the period ending March 31, 2024.
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Merck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda continued to dominate the treatment landscape.
Merck's bread-and-butter cancer drug grew by double digits again in the first quarter.
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.
MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.